Tonix Pharmaceuticals Holding Corp. Aktie News

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite Treatment was well tolerated with minimal effects on weight or blood pressure CHATHAM, N...

BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 investor conferences.

CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares o...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain

Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry

Tonix Pharmaceuticals Holding Corp. received FDA approval and launched Tonmya, the first new fibromyalgia drug in over 15 years. TNXP is expanding Tonmya into acute stress disorder [ASD] and major depressive disorder [MDD], with key phase 2 trials underway or planned to initiate. The company maintains a strong cash position, supporting operations into 2027, but future capital raises may be need...

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026